Familial hypocalciuric hypercalcemia and related disorders.

Janet Y Lee, Dolores M Shoback

Journal: Best practice & research. Clinical endocrinology & metabolism 2019;32(5):609-619

PMID: 30449544

Abstract

Familial hypocalciuric hypercalcemia (FHH) causes hypercalcemia by three genetic mechanisms: inactivating mutations in the calcium-sensing receptor, the G-protein subunit α, or adaptor-related protein complex 2, sigma 1 subunit. While hypercalcemia in other conditions causes significant morbidity and mortality, FHH generally follows a benign course. Failure to diagnose FHH can result in unwarranted treatment or surgery for the mistaken diagnosis of primary hyperparathyroidism (PHPT), given the significant overlap of biochemical features. Determinations of urinary calcium excretion greatly aid in distinguishing PHPT from FHH, but overlap still exists in certain cases. It is important that 24-h urine calcium and creatinine be included in the initial workup of hypercalcemia. FHH should be considered if low or even low normal urinary calcium levels are found in what is typically an asymptomatic hypercalcemic patient. The calcimimetic cinacalcet has been used to treat hypercalcemia in certain symptomatic causes of FHH.

Copyright © 2018 Elsevier Ltd. All rights reserved.

Address: Divisions of Endocrinology and Metabolism and Pediatric Endocrinology, Departments of Medicine and Pediatrics, University of California, San Francisco, United States. Electronic address: [email protected].; Endocrine Research Unit, San Francisco Veterans Affairs Health Care System, Department of Medicine, University of California, San Francisco, United States. Electronic address: [email protected].
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.